By Dr Diana Schuhmacher

Journal articles

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, 'Integration of whole genome sequencing analysis with unique patient-derived models reveals clinically relevant drug targets in TFCP2 fusion-defined rhabdomyosarcoma.', Mol Cancer Ther, http://dx.doi.org/10.1158/1535-7163.MCT-24-0704

Conference Abstracts

Pajic M; McLean B; Fajardo DC; Porazinski S; Upton DH; Schuhmacher D; Istadi A; Cox T; Timpson P; Wilcock DJ; Anderson KJ; Mason H; Guisot NE; Jones CD; Phillips C; Armer R, 2024, 'Combining zelasudil, a small molecule ROCK2 inhibitor, with chemotherapy or immunotherapy improves response in preclinical models of pancreatic cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CA, San Diego, Vol. 84, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2024 - 10 April 2024, http://dx.doi.org/10.1158/1538-7445.AM2024-720

Upton D; Fajardo DC; Omari S; Porazinski S; McLean B; Schuhmacher D; Istadi A; Kothari V; Finkelstein D; Machajewski T; Rock F; Turner S; Pajic M, 2024, 'Selective targeting of integrins αVβ8 and αVβ1 within the dynamic ecosystem of pancreatic cancer to improve the overall anti-tumor response', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CA, San Diego, Vol. 84, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2024 - 10 April 2024, http://dx.doi.org/10.1158/1538-7445.AM2024-6575

Back to profile page